The 61st ASH Annual Meeting: Unwrapping the Best From Hematology's Christmas
2019 ASH News Daily Editor Dr. Ayesha Zia recaps the 61st ASH Annual Meeting and Exposition which took place early December in Orlando.
Single-cell Genomics Reveals the Cellular Landscape of Bone Marrow Stromal Cells
Drs. Chowdhury and Mead review a study that provides insights into cellular heterogeneity of mouse bone marrow stromal cells, which serve as a comprehensive resource for re
Insightful critiques and informed commentary of important ongoing clinical trials
Drs. Garcia, Letai, and Kim discuss a trial investigating the use of venetoclax in combination with azacitidine for myelodysplastic syndromes.
Dr. Heidel and Dr. Lane discuss a study of the benefit and risk profile of AOP2014 in low-risk patients with polycythemia vera.
Drs. Friedberg and O'Dwyer discuss a study designed to examine the efficacy of combining nivolumab and BV with a chemotherapy backbone of AVD as initial treatment for older children and adult patients with newly diagnosed stage III or IV classical Hodgkin lymphoma.
Dr. Osunkwo reviews a study that will explore the impact of continuous positive airway pressure on improving rates of vaso-occlusive crisis as well as several biologic parameters of disease severity in individuals with SCD and comorbid obstructive sleep apnea.
Drs. Moll and Nagler discuss the CARAVAGGIO study, an ongoing trial that looks at whether apixaban can be safely and effectively used in patients with cancer and acute deep vein thrombosis or pulmonary embolism.
Dr. DeZern comments on a study in which adult patients with FLT3/ITD acute myeloid leukemia are randomized to receive gilteritinib or placebo after the time of engraftment for a two-year period.
Dr. Fenske and Dr. Kahl discuss a trial enrolling adult patients with mantle cell lymphoma (MCL), who are considered candidates for autologous hematopoietic cell transplantation, to find whether MRD status can be used to personalize therapy in MCL.
Dr. Jacobson reviews a study investigating the safety and efficacy of the anti-CD79b antibody drug conjugate, polatuzumab, in combination with R-CHP versus R-CHOP in previously untreated patients with DLBCL.
Dr. Ding and Dr. Teachey cover a trial that looks at the safety and efficacy of combining the JAK1/JAK2 inhibitor ruxolitinib with post-induction chemotherapy for pediatric patients with Philadelphia chromosome-like B-cell acute lymphoblastic leukemia.
Dr. Linkins discusses the VERDICT Trial which compares reduced doses of apixaban and rivaroxaban with standard-of-care in adult patients with symptomatic proximal deep vein thrombosis or pulmonary embolism and moderate or severe renal insufficiency.
November-December 2019Volume 16, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.